Introduction
The evaluation of interventions is a major research activity, yet the quality of descriptions of interventions in publications remains remarkably poor. Without a complete published description of the intervention, other researchers cannot replicate or build on research findings. For effective interventions, clinicians, patients, and other decision makers are left unclear about how to reliably implement the intervention. Intervention description involves more than providing a label or the ingredients list. Key features-including duration, dose or intensity, mode of delivery, essential processes, and monitoring-can all influence efficacy and replicability but are often missing or poorly described. For complex interventions, this detail is needed for each component of the intervention. For example, a recent analysis found that only 11% of 262 trials of cancer chemotherapy provided complete details of the trial treatments. 1 The most frequently missing elements were dose adjustment and "premedications," but 16% of trials omitted even the route of drug administration. The completeness of intervention description is often worse for non-pharmacological interventions: one analysis of trials and reviews found that 67% of descriptions of drug interventions were adequate compared with only 29% of non-pharmacological interventions. 2 A recent study of 137 interventions, from 133 trials of non-drug interventions, found that only 39% of interventions were described adequately in the primary paper or any references, appendices, or websites. 3 This increased, albeit to only 59%, by contacting authors for additional information-a task almost no clinicians and few researchers have time to undertake.
The Consolidated Standards of Reporting Trials (CONSORT) 2010 statement 4 currently suggests in item 5 that authors should report on "The interventions for each group with sufficient details to allow replication, including how and when they were actually administered." This is appropriate advice, but further guidance seems to be needed: despite endorsement of the CONSORT statement by many journals, reporting of interventions is deficient. The problem arises partly from lack of awareness among authors about what comprises a good description and partly from lack of attention by peer reviewers and editors. 5 A small number of CONSORT extension statements contain expanded guidance about describing interventions, such as non-pharmacological interventions, 6 and specific categories of interventions, such as acupuncture and herbal interventions. 7 8 The guidance for content of trial protocols, SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials), provides some recommendations for describing interventions in protocols. 9 More generic and comprehensive guidance is needed along with robust ways to implement such guidance. We developed an extension of item 5 of the CONSORT 2010 statement and item 11 of the SPIRIT 2013 statement in the form of a checklist and guidance entitled TIDieR (Template for Intervention Description and Replication), with the objective of improving the completeness of reporting, and ultimately the replicability, of interventions. This article describes the methods used to develop and obtain consensus for this checklist and, for each item, provides an explanation, elaboration, and examples of good reporting. While the emphasis of the checklist is on trials, the guidance is intended to apply across all evaluative study designs, such as trials, case-control studies, and cohort studies.
Methods for development of the TIDieR checklist and guide
Development of the checklist followed the methodological framework for developing reporting guidelines suggested by the EQUATOR Network. 10 In collaboration with the CONSORT steering group, we established a TIDieR steering committee (PPG, TCH, IB, RM, RP). The committee generated a list of 34 potential items from relevant CONSORT checklists and checklists for reporting discipline-specific or particular categories of interventions. The group also reviewed other sources of guidance on intervention reporting identified from a thorough search of the literature, followed by a forward and backward citation search (see appendix 1).
We then used a two round modified Delphi consensus survey method 11 involving a broad range of expertise and stakeholders. In the first round, each of the 34 items generated by the steering committee was rated by survey participants as "omit," "possible," "desirable," or "essential" to include in the final checklist. From the first round, some items were reworded and combined, and then the ranked items were divided into three groups for the second round. The first group contained 13 items with the highest rankings (rated as "essential" by ≥70% participants or "essential or desirable" by ≥85%), and participants were advised that these would be included in the checklist unless strong objection to their inclusion was received in the second round. The second group contained 13 items with moderate rankings ("essential or desirable" by ≥65%); participants were asked to rate each of these again as "omit," "possible," "desirable," or "essential." The third group contained three items with low rankings, and participants were advised that these items would be removed unless strong objection to their omission was received in the second round. In both rounds, participants could also suggest additional items, comment on item wording, or provide general comments.
Delphi participants (n=125) were authors of research on describing interventions, clinicians, authors of existing reporting guidelines, clinical trialists, methodologists or statisticians with expertise in clinical trials, and journal editors (see appendix 2). They were invited by email to complete the two rounds of the web based survey. The response rate was 72% (n=90) for the first round. Only those who completed round one and were willing to participate in round two were invited to participate in round two. The response rate for round two was 86% (74 of 86 invited).
After the two Delphi rounds, 13 items were included in the draft checklist, and 13 moderately rated items were retained for further discussion at the in person meeting. The results of the Delphi survey were reported at a two day consensus meeting on 27-28 March 2013, in Oxford, UK. Thirteen invited experts, representing a range of health disciplines (see author list) and with expertise in the development of trial, methodological, and/or reporting guidelines, attended and are all authors of this paper. The meeting began with a review of the literature on intervention reporting, followed by a report of the Delphi process, the draft checklist of 13 items, and rankings of and comments about the additional 13 moderately rated items. Meeting participants discussed the proposed items and agreed which should be included and the wording of each item.
After the meeting, the checklist was distributed to the participants to ensure it reflected the decisions made, and this explanation and elaboration document was drafted. This was then piloted with 26 researchers who were authoring papers of intervention studies and minor clarifications were made in the elaboration of some items.
Scope of the TIDieR checklist and guide for describing interventions
The overarching purpose of the TIDieR checklist is to prompt authors to describe interventions in sufficient detail to allow their replication. The checklist contains the minimum recommended items for describing an intervention. Authors should provide additional information where they consider it necessary for the replication of an intervention.
Most TIDieR items are relevant for most interventions and applicable to even apparently simple drug interventions, which are sometimes poorly described. 2 If we consider the elements of an evaluation of an intervention-the population, intervention, comparison, outcome ("PICO")-TIDieR can be seen as a guide for reporting the intervention and comparison (and co-interventions, when relevant) elements of a study. Other elements (such as population, outcomes) and methodological features are covered by CONSORT 2010 or SPIRIT 2013 items for randomised trials and by other checklists (such as the STROBE statement 12 ) for alternate study designs. They have not been duplicated as part of the TIDieR checklist.
The order in which items are presented in the checklist does not necessarily reflect the order in which information should be presented. It might also be possible to combine a number of items from the checklist into one sentence. For example, information about what materials (item 3) and what processes (item 4) can be combined (example 3c).
We emphasise that our definition of "intervention" extends to describing the intervention received by the comparison group/s in a study. Control interventions and co-interventions are often particularly poorly described; "usual care" is not a sufficient description. When a controlled study is reported, authors should describe what participants in the control group received with the same level of detail used to describe the intervention group, within the limits of feasibility. Full understanding of the comparison group care can help to explain the observed efficacy of an intervention, with greater apparent effect sizes being potentially found when control group care is minimal. 13 Describing the care that each group received will usually require the replication of the checklist for each group in a study.
As well as describing which interventions (or control conditions) were delivered to different groups, authors should also explain legitimate variants of the intervention. Authors might find it helpful to locate their trial on the pragmatic explanatory continuum.
14 If, for example in a pragmatic trial, authors expect there to be variants in aspects of the intervention (for instance, in the "usual care" group across various centres), those variants should be described under the appropriate checklist items.
We recognise that limitations (such as format and length) for journals that are only paper based can sometimes preclude inclusion of all intervention information in the primary paper (that is, the paper that is reporting the main results of the intervention evaluation). The information that is prompted by the TIDieR checklist might therefore be reported in locations beyond the primary paper itself, including online supplementary material linked to the primary paper, a published protocol and/or other published papers, or a website. Authors should specify the location of additional detail in the primary paper (for example, "online appendix 2 for the training manual," "available at www...," or "details are in our published protocol"). When websites provide further details, URLs that are designed to remain stable over time are essential.
The TIDieR checklist explanation and elaboration
The items included in the checklist are shown in 15 can help others to know which elements are essential, rather than optional or incidental. For example, the colour of capsules used in a pharmacological intervention is likely to be an incidental, not essential, contributor to the intervention's efficacy and hence reporting of this is not necessary. In some reports, the term "active ingredient" is used and refers to the components within an intervention that can be specifically linked to its effect on outcomes such that, if they were omitted, the intervention would be ineffective. 16 The known or supposed mechanism of action of the active component/s of the intervention should be described.
Example 2a illustrates the rationale for treating bacterial meningitis with dexamethasone in addition to an antibiotic. Behaviour change and implementation interventions might require different forms of description, but the basic principles are the same. It might, alongside an account of the components of the intervention, also be appropriate to describe the intervention in terms of its theoretical basis, including its hypothesised mechanisms of action (examples 2b, 2c). [17] [18] [19] The rationale behind an important element of an intervention can sometimes be pragmatic and relate to acceptability of the intervention by participants (example 2d).
Item 3. What (materials): Describe any physical or informational materials used in the intervention, including those provided to participants or used in intervention delivery or in training of intervention providers. Provide information on where the materials can be accessed (for example, online appendix, URL)
Examples:
• 3a. The educational package included a 12-minute cartoon . . . The presentation of the cartoon was complemented by classroom discussions, display of the same poster that was used for the control group [see figure in appendix 4], dissemination of a pamphlet summarising the key messages delivered in the cartoon, and drawing and essay writing competitions to reinforce the messages . . . The cartoon can be accessed at NEJM.org or at [URL provided]. A specific teacher training workshop was held before commencement of the trial (for details, see the protocol, available at NEJM.org)
• 3b. The intervention group received a behaviour change counselling training programme called the Talking Lifestyle learning programme that took practitioners through a portfolio-driven set of learning activities. Precise details of both intervention content and the training programme can be found in [URL, login and password provided]. . . Box 1 provides a more detailed description of the components of the training programme
• 3c. The "local" group received a sonographically guided injection of 2 mL (10 mg/mL) triamcinolone (Kenacort-T, Bristol-Myers Squibb) and 5 mL (10 mg/mL) lidocaine hydrochloride (Xylocaine, AstraZeneca) to the subacromial bursa and an intramuscular injection of 4 mL (10 mg/mL) lidocaine hydrochloride to the upper gluteal region
Explanation-A full description of an intervention should describe what different physical and information materials were used as part of the intervention (this typically will not extend to study consent forms unless they provide written instructions about the intervention that are not provided elsewhere). Intervention materials are the most commonly missing element of intervention descriptions. 3 This list of materials can be regarded as comparable with the "ingredients" required for a recipe. It can include materials provided to participants (example 3a), training materials used with the intervention providers (examples 3a, 3b), or the surgical device or pharmaceutical drug used and its manufacturer (example 3c). For some interventions, it might be possible to describe the materials and the procedures (item 4) together (examples 3c, 4c) . If the information is too long or complex to describe in the primary paper, alternative options and formats for providing the materials should be used (see appendix 4 for some examples) and details of where they can be obtained (examples 3a, 3b) should be provided in the primary paper. These clearance manoeuvres were performed over 1.5 min.
The second period consisted of 1 min of stretching repeated five times, followed by the same expiratory manoeuvres for 1.5 min, as described above. The third period consisted of continuous jumping on a small trampoline. It included 2 min of jumping, 2 min of jumping while throwing and catching a ball, and 1 min of jumping while hitting a tossed ball. This was again followed by expiratory manoeuvres for 1.5 min. The entire regimen was followed by 40 min rest • 5b. The procedure is simple, uses existing surgical skills, and has a short learning curve, with the manufacturers recommending at least five mentored cases before independently practising. All surgeons involved in the study will have completed this training and will have carried out over five procedures prior to recruiting to the study • 5c. Therapists received at least one day of training specific to the trial from an experienced CBT [cognitive behaviour therapy] therapist and trainer and weekly supervision from skilled CBT supervisors at each centre. . . The intervention was delivered by 11 part time therapists in the three sites who were representative of those working within NHS psychological services [reference] . Ten of the 11 therapists were female, their mean age was 39.2 years (SD 8.1), and they had practised as a therapist for a mean of 9.7 years (8.1) . . . Nine of the 11 therapists delivered 97% of the intervention and, for these nine, the number of patients per therapist ranged from 13 (6%) to 41 (18%)
• 5d. . . . brief lifestyle counselling was practised with trained actors and tape recorded. The competency of counselling was checked using the behaviour change counselling index [reference] . Only practitioners who reached a required standard (agreed by inter-rater consensus between three independent clinical assessors) were approved to deliver brief lifestyle counselling in the trial Explanation-The term "intervention provider" refers to who was involved in providing the intervention (for example, by delivering it to recipients or undertaking specific tasks). This is important in circumstances where the providers' expertise and other characteristics (example 5a) could affect the outcomes of the intervention. Important issues to address in the description might include the number of providers involved in delivering or undertaking the intervention; their disciplinary background (for example, nurse, occupational therapist, colorectal surgeon, expert patient); what pre-existing specific skills, expertise, and experience providers required and if and how these were verified; details of any additional training specific to the intervention that needed to be given to providers before (example 3b) and/or during the study (example 5c); and if competence in delivering the intervention was assessed before (example 5d) or monitored throughout the study and whether those deemed lacking in competence were excluded (example 5d) or retrained. Other information about providers could include whether the providers were doing the intervention as part of their normal role (example 3b) or were specially recruited as providers for purposes of the study (example 5c); whether providers were reimbursed for their time or provided with other incentives (if so, what) to deliver the intervention as part of the study, and whether such time or incentives might be needed to replicate the intervention. Explanation-The type of information needed about the "when and how much" of the intervention will differ according to the type of intervention. For some interventions some aspects will be more important than others. For example, for pharmacological interventions, the dose and scheduling is often important (example 8a); for many non-pharmacological interventions, the "how much" of the intervention is instead described by the duration and number of sessions (examples 8b, 8c). For multiple session interventions, the schedule of the sessions is also needed (example 8b) and if the number of sessions, their schedule, and/or intensity was fixed (examples 8b, 4c, 6a) or if it could be varied according to rules and if so, what they were (example 8c). Tailoring of the intervention to individuals or groups of individuals is elaborated on in item 9 (tailoring). For some interventions, as part of the "when" information, detail about the timing of the intervention in relation to relevant events might also be important (for example, how long after diagnosis, first symptoms, or a crucial event did the intervention start) (example 8d). As described below in item 12, the "amount" or dose of intervention that participants actually received might differ from the amount intended. This detail should be described, usually in the results section (examples 12a-c). Examples:
• 10a. A mixture of general practitioners and practice care nurses delivered 95% of screening and brief intervention activity in this trial. . . Owing to this slow recruitment, research staff who had delivered training in study procedures supported screening and brief intervention delivery in 10 practices and recruited 152 patients, which was 5% of the total number of trial participants
• 10b. Computers with slow processing units and poor internet connections meant that seven general practitioners never got functional software; they used a structured paper version that was faxed between the research team and general practitioner after each appointment
Explanation-This item refers to modifications that occur at the study level, not individual tailoring as described in item 9. Unforeseen modifications to the intervention can occur during the course of the study, particularly in early studies. If this happens, it is important to explain what was modified, why and when modifications occurred, and how the modified intervention differed from the original (example 10a-modification to who provided the intervention; example 10b-modification in the materials). Modifications sometimes reflect changing circumstances. In other studies, they can show learning about the intervention, which is important to transmit to the reader and others to prevent unnecessary repetition of errors during attempts to replicate the intervention. If changes to the intervention occurred between the published protocol or published pilot study and the primary paper, these changes should also be described.
Item 11. How well (planned): If intervention adherence or fidelity was assessed, describe how and by whom, and if any strategies were used to maintain or improve fidelity, describe them
• 11a. Pathologists were trained to identify lateral spread of tumour according to the protocol [reference]. The results of histopathological examination of the specimens were reviewed by a panel of supervising pathologists and a quality manager
• 11b. Staff in the study sites were trained initially, and therapy supervision was provided by weekly meetings between therapists and investigators. Cognitive therapy sessions were taped with the participant's consent so that participants could be asked to listen to the tapes as part of their homework and to assist supervision. During the course of the trial a sample of 80 tapes was rated according to the cognitive therapy scale-revised [reference] and the cognitive therapy for at risk populations adherence scale [reference] to ensure rigorous adherence to the protocol throughout the duration of the trial. These tapes were drawn from both early and late phases of therapy and included participants from each year of recruitment
• 11c. Adherence to trial medication was assessed by means of self reported pill counts collected during follow-up telephone calls. These data were categorised as no pills taken, hardly any taken (1-24% of prescribed doses), some taken (25-49%), most taken (50-74%), or all taken (75-100%)
• 11d. Training will be delivered independently in each of the three regional study centres. All trainers will adhere to a single training protocol to ensure standardised delivery of the training across centres. Training delivery will be planned and rehearsed jointly by all trainers using role play and peer review techniques. In addition, the project manager will act as an observer during the first two training sessions in each centre and will provide feedback to trainers with a view to further standardising the training [note, this example is from a protocol]
Explanation-Fidelity refers to the degree to which an intervention happened in the way the investigators intended it to 20 and can affect the success of an intervention. 21 The terms used to describe this concept vary among disciplines and include treatment integrity, provider or participant adherence, and implementation fidelity. This item-and item 12-extends beyond simple receipt of the intervention (such as how many participants were issued with the intervention drug or exercises) and refers to "how well" the intervention was received or delivered (such as how many participants took the drug/did the exercises, how much they took/did, and for how long). Depending on the intervention, fidelity can apply to one or more parts of the intervention, such as training of providers (examples 11a, 11b, 11d), delivery of the intervention (example 11b), and receipt of the intervention (example 11c). The types of measures used to determine intervention fidelity will also vary according to the type of intervention. For example, in simple pharmacological interventions, assessing fidelity often focuses on recipients' adherence to taking the drug (example 11b). In complex interventions, such as rehabilitation, psychological, or behaviour change interventions, however, assessment of fidelity is also more complex (example 11b). There are various preplanned strategies and tools that can be used to maintain fidelity before delivery of the intervention (example 11d) or during the study (example 11b). If any strategies or tools were used to maintain fidelity, they should be clearly described. Any materials used as part of assessing or maintaining fidelity should be included, referenced, or their location provided. and treatment related barriers to exercise during their cancer treatment ("week of chemotherapy" 14%; "fatigue" 10%); or life related barriers ("illness eg, colds or flu" 16%; "family obligations" 13%)"
• 12c. A total of 214 participants (78%) reported taking at least 75% of the study tablets; the proportion of patients who reported taking at least 75% of the tablets was similar in the two groups
• 12d. The integrity of the psychological therapy was assessed with the cognitive therapy rating scale [reference] to score transcripts of 40 online sessions for patients who had completed at least five sessions of therapy. With use of computer generated random numbers, at least one such patient was selected for each therapist. For these patients, either session six or the penultimate session was rated by two independent CBT [cognitive behaviour therapy]-trained psychologists, who gave mean ratings of 31 (SD between therapists 9) and 32 (13) of 72
Explanation-For various reasons, an intervention, or parts of it, might not be delivered as intended, thus affecting the fidelity of the intervention. If this is assessed, authors should describe the extent to which the delivered intervention varied from the intended intervention. This information can help to explain study findings, minimise errors in interpreting study outcomes, inform future modifications to the intervention, and, when fidelity is poor, can point to the need for further studies or strategies to improve fidelity or adherence. 22 23 For example, there might be some aspects of the intervention that participants do not like and this could influence their adherence. The way in which the intervention fidelity is reported will reflect the measures used to assess it (examples 12a-d), as described in item 11.
Discussion
Who should use TIDieR?
We describe a short list of items that we believe can be used to improve the reporting of interventions and make it easier for authors to structure accounts of their interventions, reviewers and editors to assess the descriptions, and readers to use the information. Consistent with the CONSORT 2010 and SPIRIT 2013 statements, we recommend that interventions are described in enough detail to enable replication, and recommend that authors use the TIDieR checklist to achieve this. As inclusion of all intervention details is not always possible in the primary paper of a study, the TIDieR checklist encourages authors to indicate that they have reported each of the items and to state where this information is located (see appendix 3).
The number of checklist items reported is improved when journals require checklist completion as part of the submission process. 24 We encourage journals to endorse the use of the TIDieR checklist, in a similar way to CONSORT and related statements. This can be done by modifying their author instructions, publishing an editorial about intervention reporting, and including a link to the checklist on their website. Few journals currently provide specific guidance about how to report interventions. 25 A small number have editorial policies stating that they will not publish trials unless intervention protocols or full details are available. 26 We encourage other journals to consider adopting similar policies. Any links provided by journals and authors should be reliable and enduring. Stable depositories for descriptions of interventions are also required, and their development needs the contribution and collaboration of all stakeholders in the research community (such as researchers, journal editors, publishers, research funding bodies).
Authors might also want to be guided by the TIDieR items when describing interventions in systematic reviews so that readers of reviews have access to full details of any intervention (or at least details about where to obtain further information) that they want to replicate after reading the review.
Using TIDieR in conjunction with the CONSORT and SPIRIT Statements
For authors submitting reports of randomised trials, we suggest using the TIDieR in conjunction with the CONSORT checklist: when authors complete item 5 of the CONSORT checklist, they should insert "refer to TIDieR checklist" and provide a separate completed TIDieR checklist. For journals that adopt this recommendation, their instructions to authors will need to be modified accordingly and their editors and reviewers made aware of the change. Similarly, for authors submitting protocols of trials, the TIDieR checklist can be referred to when dealing with item 11 of the SPIRIT 2013 checklist. One point of difference is that two TIDieR items (items 10 and 12) are not applicable to intervention reporting in protocols because they cannot be completed until the study is complete. This is noted on the TIDieR checklist. Published protocols are likely to grow in importance as a source of information about the intervention and use of TIDieR in conjunction with the SPIRIT 2013 statement can facilitate this. For authors of study designs other than randomised trials, TIDieR can be used alone as a standalone checklist or in conjunction with the relevant statement for that study design (such as the STROBE statement 12 ). We acknowledge that describing complex interventions well can be challenging and that for some particularly complex interventions, a checklist, such as TIDieR, could go some way towards assisting with intervention reporting but might not be able to capture the full complexity of these interventions.
We recognise that adhering to the TIDieR checklist might increase the word count of a paper, particular if the study protocol is not publicly available. We believe this might be necessary to help improve the reporting of studies generally and interventions specifically. As journals recognise the importance of well reported studies and fully described methods, and many move to a model of online only, or a hybrid of printed and online with posting of the full study protocol, this might become less of a barrier to quality reporting. For example, the Nature Publishing Group recently removed word limits on the methods section of submitted papers and advises that: "If more space is required to describe the methods completely, the author should include the 300-word section 'Methods Summary' and provide an additional 'Methods' section at the end of the text, following the figure legends. This Methods section will appear in the online . . . version of the paper, but will not appear in the printed issue. The Methods section should be written as concisely as possible but should contain all elements necessary to allow interpretation and replication of the results."
27

Conclusion
The TIDieR checklist and guide should assist authors, editors, peer reviewers, and readers. Some authors might perceive this checklist as another time consuming hurdle and elect to seek publication in a journal that does not endorse reporting guidelines. There is a large evidence base indicating that the quality of reporting of health research is unacceptably poor. Properly endorsed and implemented reporting guidelines offer a way for publishers, editors, peer reviewers, and authors to do a better job of completely and transparently describing what was done and found.
28 Doing so will help reduce wasteful research 29 30 and increase the potential impact of research on health.
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Summary points
Without a complete published description of interventions, clinicians and patients cannot reliably implement effective interventions
The quality of description of interventions in publications, regardless of type of intervention, is remarkably poor The Template for Intervention Description and Replication (TIDieR) checklist and guide has been developed to improve the completeness of reporting, and ultimately the replicability, of interventions TIDieR can be used by authors to structure reports of their interventions, by reviewers and editors to assess completeness of descriptions, and by readers who want to use the information Tables   Table 1| Items 
Brief name
Provide the name or a phrase that describes the intervention 1
Why
Describe any rationale, theory, or goal of the elements essential to the intervention 2
What
Materials: Describe any physical or informational materials used in the intervention, including those provided to participants or used in intervention delivery or in training of intervention providers. Provide information on where the materials can be accessed (such as online appendix, URL) 
Who provided
For each category of intervention provider (such as psychologist, nursing assistant), describe their expertise, background, and any specific training given 5
How
Describe the modes of delivery (such as face to face or by some other mechanism, such as internet or telephone) of the intervention and whether it was provided individually or in a group 6
Where
Describe the type(s) of location(s) where the intervention occurred, including any necessary infrastructure or relevant features 7
When and How Much
Describe the number of times the intervention was delivered and over what period of time including the number of sessions, their schedule, and their duration, intensity, or dose 8
Tailoring
If the intervention was planned to be personalised, titrated or adapted, then describe what, why, when, and how 9
Modifications
If the intervention was modified during the course of the study, describe the changes (what, why, when, and how) 10*
How well
Planned: If intervention adherence or fidelity was assessed, describe how and by whom, and if any strategies were used to maintain or improve fidelity, describe them 11 Actual: If intervention adherence or fidelity was assessed, describe the extent to which the intervention was delivered as planned 12* *If checklist is completed for a protocol, these items are not relevant to protocol and cannot be described until study is complete.
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